Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of enrofloxacin powder cas 93106-60-6 in China. Welcome to wholesale bulk high quality enrofloxacin powder cas 93106-60-6 for sale here from our factory. Good service and reasonable price are available.
Enrofloxacin powder, also known as ethyl ciprofloxacin or enrofloxacin, is an important animal specific drug and belongs to the fluoroquinolone class of chemically synthesized antibacterial agents. It usually appears as a white or slightly yellow crystalline powder, and its appearance may vary slightly due to different production processes and storage conditions. This powder is odorless, odorless, and has a good crystalline form, making it easy to process formulations. The solubility in water is low and almost insoluble, which limits its direct application in aqueous solutions. However, it has good solubility in certain organic solvents, such as sodium hydroxide solution, methanol, and cyanomethane. In addition, under acidic or alkaline conditions, solubility can be improved, which allows for the optimization of dissolution performance during the formulation process by adjusting the pH value of the solution. It has bactericidal effects on various bacteria, especially on some Gram negative bacteria such as Escherichia coli and pneumococci, showing strong antibacterial activity. Used to treat respiratory infections, including chronic bronchitis, pneumonia, and other diseases, especially infections caused by bacteria with strong drug resistance. It is also commonly used to treat urinary and reproductive system infections, such as urethritis, epididymitis, etc., and has a good therapeutic effect on some Gram negative bacteria.
|
|
|
|
Chemical Formula |
C19H22FN3O3 |
|
Exact Mass |
359 |
|
Molecular Weight |
359 |
|
m/z |
359 (100.0%), 360 (20.5%), 361 (2.0%), 360 (1.1%) |
|
Elemental Analysis |
C, 63.50; H, 6.17; F, 5.29; N, 11.69; O, 13.35 |
Enrofloxacin powder, as a third-generation quinolone broad-spectrum antibacterial drug, has shown significant antibacterial effects against various bacteria in veterinary clinical practice. Its strong antibacterial activity and broad antibacterial spectrum make enrofloxacin an important drug for treating infectious diseases in livestock and poultry and aquaculture.
Enrofloxacin has a strong antibacterial effect on a variety of gram-negative bacteria, which often cause serious infectious diseases in the aquaculture industry. Specifically, enrofloxacin exhibits significant antibacterial effects against the following Gram negative bacteria:
1. Escherichia coli:
Escherichia coli is one of the common pathogens in the aquaculture industry, which can cause a variety of infectious diseases. Enrofloxacin has a strong bactericidal effect on Escherichia coli and can effectively control its infection. Research has shown that enrofloxacin has a lower minimum inhibitory concentration (MIC) against Escherichia coli, indicating its strong antibacterial activity against Escherichia coli.
2. Pseudomonas aeruginosa (Pseudomonas aeruginosa):
Although some articles mention that norfloxacin (note that although norfloxacin and enrofloxacin are similar drugs, they may not be the same, and there may be confusion here) is ineffective against Pseudomonas aeruginosa, enrofloxacin, as a broad-spectrum antibacterial drug, also has certain antibacterial effects against Pseudomonas aeruginosa. However, its antibacterial activity may vary depending on the strain.
3. Salmonella:
Salmonella is a common pathogen that causes food poisoning and intestinal infections in livestock, poultry, and aquaculture. Enrofloxacin has a strong bactericidal effect on Salmonella, which can effectively control Salmonella infection and reduce the spread and occurrence of diseases.
4. Other Gram negative bacteria:
Enrofloxacin has also shown significant antibacterial effects against various Gram negative bacteria such as Citrobacter, Acinetobacter, Haemophilus influenzae, and Neisseria gonorrhoeae. These bacteria may also cause serious infectious diseases in the aquaculture industry, and the application of enrofloxacin will help to control the occurrence and spread of these diseases.
5. Klebsiella pneumoniae:
Klebsiella pneumoniae is one of the important pathogens that cause respiratory infections. Enrofloxacin also exhibits significant antibacterial effects on Klebsiella pneumoniae, effectively inhibiting its growth and reproduction.
Antibacterial effect on Gram positive bacteria
Enrofloxacin not only has a strong antibacterial effect on Gram negative bacteria, but also exhibits good antibacterial effects on some Gram positive bacteria. These gram-positive bacteria may also cause infectious diseases in the aquaculture industry. Specifically, enrofloxacin exhibits significant antibacterial effects against the following Gram positive bacteria:
1. Streptococcus pneumoniae:
Streptococcus pneumoniae is a common pathogen that causes respiratory infections. Enrofloxacin also showed good antibacterial activity against Streptococcus pneumoniae, helping to control infectious diseases caused by Streptococcus pneumoniae.
2. Streptococcus pyogenes:
Streptococcus pyogenes is one of the pathogens that cause purulent infections. The antibacterial effect of enrofloxacin on Streptococcus pyogenes is also worth noting, which helps to reduce the occurrence of infectious diseases caused by Streptococcus pyogenes.
3. Digital and data support for antibacterial effects
To provide a more specific explanation of the antibacterial effect of enrofloxacin, the following are some relevant numbers and data support:
Enrofloxacin has a low MIC value for various pathogens, such as Escherichia coli, Salmonella, and other Gram negative bacteria, typically ranging from 0.008 to 0.750 g/mL. This indicates that enrofloxacin has strong antibacterial activity against these pathogens.
In clinical application, enrofloxacin is often used to treat infectious diseases caused by sensitive bacteria, such as piglet white dysentery, yellow dysentery, edema type colibacillosis, etc. The cure rate of these diseases is often high, such as using enrofloxacin to treat E. coli induced edema disease in pigs, with a cure rate of over 90%.
Enrofloxacin has good pharmacokinetic properties in animals, with a long half-life and wide tissue distribution. This allows enrofloxacin to maintain an effective drug concentration in the body for a longer period of time, thereby better exerting its antibacterial effect.
Enrofloxacin powder, as an important broad-spectrum quinolone antibacterial drug, has significant pharmacological effects in veterinary clinical practice.
1. Pharmacological mechanism of action
The pharmacological effects of enrofloxacin are mainly based on its unique antibacterial mechanism. As a quinolone drug, enrofloxacin achieves antibacterial effects by inhibiting the activity of bacterial DNA gyrase and topoisomerase IV, interfering with the normal synthesis process of bacterial DNA. Specifically, enrofloxacin can tightly bind to subunit A of bacterial DNA gyrase, blocking the enzyme's ability to cut and connect DNA, thereby blocking the replication and transcription process of bacterial DNA, preventing further proliferation and death.
2. Pharmacokinetic characteristics
The pharmacokinetic properties of enrofloxacin in animals are excellent, providing strong support for its widespread clinical application. Specifically, the pharmacokinetic characteristics of enrofloxacin include the following aspects:
1. Absorption and distribution:
Enrofloxacin is rapidly and completely absorbed in animal bodies. After administration through various methods such as oral administration, intramuscular injection, or subcutaneous injection, it can quickly distribute to various tissues and organs throughout the body. Except for the central nervous system, the drug concentration of enrofloxacin in most tissues is higher than that in plasma, which is beneficial for its treatment of systemic and deep tissue infections.
2. Metabolism and excretion:
The metabolism of enrofloxacin in animals mainly occurs in the liver and kidneys. The main metabolite is ciprofloxacin, which still retains strong antibacterial activity. Enrofloxacin is eliminated through both renal and non renal means, with approximately 15% to 50% of the drug being excreted through urine. This excretion method helps to reduce the accumulation of drugs in the body and potential toxic reactions.
3. Therapeutic effects on specific infections
Enrofloxacin has shown good therapeutic effects on many infectious diseases in veterinary clinic. Here are some typical application examples:
1. Respiratory infections:
Enrofloxacin is commonly used to treat respiratory infections caused by sensitive bacteria, such as chronic bronchitis, pneumonia, etc. Its strong antibacterial activity and wide tissue distribution enable enrofloxacin to effectively control the pathogens of respiratory infections, alleviate clinical symptoms, and promote disease recovery.
2. Urinary and reproductive system infections:
Enrofloxacin is also commonly used to treat urinary and reproductive system infections, such as urethritis, epididymitis, etc. Its broad antibacterial spectrum and strong antibacterial activity against gram-negative bacteria make enrofloxacin have significant advantages in the treatment of such infectious diseases.
3. Digestive system infections:
Enrofloxacin can be used to treat some digestive system infections, such as gastrointestinal infections. It achieves antibacterial effects by inhibiting the synthesis of bacterial DNA, effectively controlling the pathogens of gastrointestinal infections, and alleviating clinical symptoms such as diarrhea and abdominal pain.
4. Other infectious diseases:
Enrofloxacin powder can also be used to treat skin and soft tissue infections, sepsis and other infectious diseases. Its broad-spectrum antibacterial activity and good tissue distribution make enrofloxacin also have significant effects in the treatment of these infectious diseases.
Enrofloxacin, as a third-generation fluoroquinolone animal specific antibacterial drug, has a development history spanning more than half a century, from basic research to clinical application, from single formulation to compound innovation, gradually becoming an indispensable antibacterial drug in the global aquaculture and livestock breeding fields. This process not only reflects the deep integration of chemical synthesis technology and pharmacological research, but also reflects the continuous exploration of human needs for animal health and food safety.
Origin: Breakthrough from Quinolones to Animal specific Antibiotics
The research and development stems from a deep understanding of the antibacterial mechanism of quinolone drugs. In 1962, the first generation quinolone drug nalidixic acid was introduced, mainly used to treat human urinary tract infections, but its antibacterial spectrum is narrow and prone to drug resistance. In 1979, the third-generation quinolone drug norfloxacin was born, which significantly enhanced its activity against Gram negative bacteria and reduced its toxicity to the central nervous system by introducing fluorine atoms and piperazine groups. However, these drugs still face issues such as cross resistance and insufficient tissue permeability, which limit their application in animal farming.
In the early 1980s, the research team of Bayer in Germany began developing new quinolone drugs to meet the special needs of animal farming. They successfully synthesized enrofloxacin by introducing cyclopropyl and ethylpiperazine groups on the basis of its structure. This innovative design not only retains the broad-spectrum antibacterial activity of third-generation quinolone drugs, but also further enhances the inhibitory effect of drugs on Gram positive bacteria, mycoplasma, and chlamydia. At the same time, it enhances lipid solubility and tissue permeability, allowing it to quickly distribute in various tissues of the animal body, including the blood-brain barrier and placental barrier. In 1987, enrofloxacin was first launched in New Zealand, becoming the world's first third-generation fluoroquinolone drug specifically designed for animals, marking the entry of animal antibiotics into the era of "precision therapy".
Development: Global Promotion and the Rise of Aquaculture
The promotion of enrofloxacin benefits from its unique pharmacological advantages and strict regulatory certification. In 1996, the US Food and Drug Administration (FDA) approved enrofloxacin for use in livestock and aquaculture, stating that it can treat infections caused by Escherichia coli, Salmonella, Pasteurella, and other bacteria. The European Union, Japan and other countries and regions have also included it in the list of allowed animal medicines, but they all emphasize the need to strictly comply with the rest period regulations to ensure food safety. For example, the European Union has set the maximum residue limit (MRL) of enrofloxacin in pork, cattle, and poultry muscles at 0.1 μ g/g, with a rest period ranging from 3 to 28 days depending on the animal species and mode of administration.
In China, the research and application of enrofloxacin started relatively late but developed rapidly. In 1993, China successfully synthesized Enrofloxacin API, breaking the foreign technological monopoly. In the late 1990s, with the large-scale development of aquaculture, bacterial diseases occurred frequently. Enrofloxacin quickly became the first choice drug for the treatment of fulminant bleeding, gill rot, and enteritis due to its highly effective inhibitory effect on aquatic pathogens such as Aeromonas hydrophila, Vibrio vulnificus, and Edwardsiella. For example, studies have shown that the minimum inhibitory concentration (MIC) of enrofloxacin against Vibrio parahaemolyticus in South American white shrimp is only 0.45mg/L, and the MIC against Yersinia pestis in fish is as low as 0.005mg/L, significantly better than traditional drugs such as tetracycline and florfenicol.
Hot Tags: enrofloxacin powder cas 93106-60-6, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Meglumine powder, Atropine Sulfate Monohydrate CAS 5908 99 6, Primidone powder, Cyclophosphamide monohydrate powder, 1 Naphthaleneacetic Acid CAS 86 87 3, Scopolamine Butylbromide